RSS

Polyphor

Polyphor — a clinical stage Swiss biopharmaceutical company — has raised CHF 6.8 million from the Novo REPAIR Impact Fund to accelerate the development of novel antibiotics against multi-drug resistant Gram-negative pathogens. more

News

Swiss-based specialty pharma company, Polyphor, has announced that the first patient has been enrolled in the Phase III clinical trial for murepavadin — a pathogen-specific antibiotic being developed for the treatment of nosocomial pneumonia more

News

Polyphor has been awarded with its first milestone payment from the Wellcome Trust ahead of schedule for the development of novel antibiotics against Gram-negative multidrug-resistant pathogens. more

News

Clinical stage, Swiss speciality pharma company, Polyphor, has presented promising data on the Outer Membrane Protein Targeting Antibiotics (OMPTA), which is a class of antibiotic against gram-negative pathogens. more

News

Clinical-stage Swiss speciality pharma company, Polyphor, has announced the completion of a CHF40 million private placement. The majority of the financing (98%) was provided by existing investors. more

News